J&J joins $10.6M round for developer of stem cell treatment

07/11/2013 | Xconomy

Stem cell startup ViaCyte secured $10.6 million in a private equity funding round in which Johnson & Johnson, the Johnson Trust and Sanderling Ventures participated. The funding matches the $10.1 million grant approved last year by the California Institute for Regenerative Medicine to support clinical trials of ViaCyte's encapsulated cell therapy product, VC-01, for treatment of type 1 and insulin-dependent type 2 diabetes.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA